Anglo-Swedish drugmaker AstraZeneca said on Tuesday a study of its monoclonal antibody treatment, AZD7442, did not meet the main goal of preventing symptomatic Covid-19 in people recently exposed to the novel coronavirus. The company said the participants in the trial were unvaccinated adults older than 18 years with confirmed exposure to a person with the coronavirus within the past eight days. AZD7442 reduced the risk of developing symptomatic Covid-19 by 33% compared to a placebo, which was not statistically significant, the company reported. ‘While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative parti
Hence then, the article about astrazeneca says antibody treatment failed in preventing covid 19 in exposed patients was published today ( ) and is available onٌRayaٌ news ( Qatar ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( AstraZeneca says antibody treatment failed in preventing Covid-19 in exposed patients )